Strainsforpains CEO Simon Shainberg Discusses Entering 191 Billion Dollar Anti-Inflammatory Market, and Strategic Partnership and Research Potential with GenBio Corp.

NEW YORK, March 14, 2024 (GLOBE NEWSWIRE) -- Strainsforpains, Inc. (OTC PINK:EBYH)

Strainsforpains, Inc. has entered into a strategic partnership with GenBio to license potentially new anti-inflammatory compounds to be included in Strainsforpains CBD branded products. Strainsforpains is also progressing towards its change of symbol on the OTC Markets, with its upcoming audited financials within 2024.

“Our company is very involved, and has been for a long time, in the health and wellness space,” said Simon Shainberg, CEO of Strainsforpains, Inc. “Giles Tilley of GenBio is an absolute authority on natural extracts, the science behind them, and how to be able to refine the extracts from those products. When Giles and I first met it became obvious to both of us that there was a tremendous synergy there.”

GenBio is primarily a US-based biotech research Company, and its mission is to develop the next generation of anti-inflammatory drugs. In Australia, there are natural extracts that demonstrate outstanding potential in the medical and health field. GenBio has reviewed numerous natural extracts over the last five years.

These novel extracts also have the possibility to be added to CBD formulations. The unique selling point of these extracts is their potential to be additive or synergistic (or both) to CBD and thus complement CBD with either a new Mechanism of Action or alternatively strengthen the activity of the inherent CBD. Targeted future research will establish this more clearly. GenBio’s current research program is a potentially powerful anti-inflammatory drug program with lower toxicity than existing pharmaceutical drugs. A spin-off nutraceutical research program is now anticipated to validate the relevant findings. They will also hope to enter an Investigational New Drug program in the United States in the next months.

“The health and wellness space, following the pandemic, is now a much larger space where customers are much more interested in their personal health, as well as the education behind that,” said Shainberg. “Having the science supplied by GenBio and having unique products that are aimed specifically at these issues, we believe, will give us the edge in that market. We believe this is going to dovetail into our company's sales and operations and will hit our bottom line in the next two to four quarters.”